Journal article
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial
Abstract
BACKGROUND: Low dose rivaroxaban with aspirin reduced major cardiovascular events (MACE) compared to aspirin alone in patients with cardiovascular disease although effects on total events are unknown.
METHODS: The COMPASS clinical trial randomized 27,395 participants with chronic coronary and/or peripheral artery disease to rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily, rivaroxaban 5 mg twice daily alone, or aspirin 100 mg daily. We …
Authors
Branch KRH; Probstfield JL; Bosch J; Bhatt DL; Maggioni AP; Muehlhofer E; Avezum A; Widimsky P; Connolly SJ; Yi Q
Journal
American Heart Journal, Vol. 258, , pp. 60–68
Publisher
Elsevier
Publication Date
April 2023
DOI
10.1016/j.ahj.2023.01.008
ISSN
0002-8703